Consumer Alert: FDA Panel Urges Stronger Child and Adolescent Suicide Warnings on Antidepressants, including Paxil, Zoloft and Effexor

September 15, 2004

A panel of expert advisers recommended on September 15, 2004, to the FDA that antidepressants should come with the nation's strongest warning -- in a black box on the label -- that children and teenagers taking these drugs may be at an increased risk for suicidal behavior. The recommendation applies to all antidepressants, including Paxil, Zoloft and Effexor.

In addition, the panel recommended that antidepressants prescribed to minors should be accompanied by an easy-to-read pamphlet that explains how to decide if a child is a good patient for the drug, and lists the warning signs of suicide. The panel also urged the FDA to consider having parents sign a form indicating that they understand the risks before the child receives antidepressants. The panel's actions are based upon its review of scientific studies concerning the drugs. FDA predicts that it will act upon the recommendations– FDA usually follows the recommendations of its advisory panels– within a few months.

The drugs are approved by the FDA for use in adults, but there has not been a showing that Paxil, Zoloft or Effexor are effective in treating depression in children. Paxil is manufactured GlaxoSmithKline, Zoloft by Pfizer and Effexor by Wyeth.

There have been some legal cases involving antidepressants, including Paxil. If you have questions of a legal nature, please contact Gary Wilson or Tara Sutton at Robins, Kaplan, Miller & Ciresi L.L.P.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.

Disclaimer

Tara D. Sutton

Partner

Chair, National Mass Tort Group;
Member of Executive Board

Related Publications

Fall 2021
Are All Fiduciaries Created Equal?
Erica Ramsey - The Robins Kaplan Spotlight, Vol. 6, No. 3
Fall 2021
Context Matters: Fiduciaries and the Rule Against Self-Dealing
Brendan Johnson, Tim Billion - The Robins Kaplan Spotlight, Vol. 6, No. 3
Fall 2021
Update on DOL Fiduciary Rule
Michael Reif - The Robins Kaplan Spotlight, Vol. 6, No. 3
September 28, 2021
Briefly: Federal appeals: How much notice is enough?
Stephen Safranski and Geoffrey Kozen - Minnesota Lawyer
Summer 2021
IATL President's Letter on Judicial Security
Roman Silberfeld - The Robins Kaplan Quarterly: Tackling Tough Business Litigation Matters
Back to Top